What is ROIV's market cap?

$27.61B, based on the Nov 4 close of $38.23.

Does Roivant Sciences Ltd. Common Shares pay a dividend?

No regular cash dividend has been paid in the last year.

How much of ROIV is sold short?

40.3M shares, 8.0% of float, as of Oct 15, 2026.

What sector is ROIV in?

Healthcare, in the Pharmaceuticals industry.

NASDAQ · ROIVHealthcarePharmaceuticals

Roivant Sciences Ltd. Common Shares (ROIV)

$38.23+6.08%

Close Nov 4, 2026 · split-adjusted

Nov 3, 2026$36.47▲ 86.07% in range

Nov 3, 2025Low $19.60 · High $41.81Nov 3, 2026

What changed · written from our data

As of Nov 4, 2026

Roivant Sciences Ltd. Common Shares closed at $38.23 on Nov 4, up 6.08%, 8.6% below its 52-week closing high. Volume of 11.7M shares was 1.74× its 20-day average (above normal).

Split-adjusted performance: +7.6% over one month, +32.7% over six months, +95.1% over one year.

In the quarter ended Jun 30, 2026, revenue was $1.44M, down 33.5% from a year earlier, with a net margin of -13164.8%.

Short interest was 40.3M shares at the Oct 15 settlement, up 2.6% from the prior report (8.0% of float, 7.9 days to cover).

Market cap$27.61B722.3M shares

Revenue · quarter$1.4M−33.5% YoY

Diluted EPS$-0.26—

P/E · TTM—P/S 3,666.3×

Net margin-13,164.8%Gross 100.0%

Dividend yieldNone

52-week range19.60 – 41.81−8.6% from high

Volume11.7M1.74× 20-day avg

Volatility · 60d50.3%Annualised

Short % of float8.0%7.9 days to cover

Net cash$3.84BCash $3.84B

Next earnings—Not scheduled

Split-adjusted performance

1W +3.0%1M +7.6%3M +8.9%6M +32.7%YTD +76.2%1Y +95.1%3Y +352.4%5Y +393.9%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Pharmaceuticals

Percentile among 420 companies (100 = best)

6-month momentum87

Revenue growth25

Net margin4

Value (low P/E)—

Size97

Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.

Short interest

Details →

Shares short40.3M+2.6% vs prior

Days to cover7.9Settled Oct 15

% of float8.0%

Short vol. 10d64.6%of daily volume

Closest peers by size in Pharmaceuticals

Company	Price	Today	6M	Rev. growth	Net margin	P/E	Mkt cap
ROIVRoivant Sciences	$38.23	+6.08%	+32.7%	−33.5%	−13164.8%	—	$27.61B
UTHRUnited Therapeutics	$608.49	+1.19%	+2.0%	−1.9%	42.5%	19.9	$26.10B	Compare
RPRXRoyalty Pharma	$67.56	+1.75%	+33.2%	+16.5%	2.7%	36.9	$30.08B	Compare
INSMInsmed	$110.00	+5.32%	−19.8%	+268.4%	−19.1%	—	$24.13B	Compare
VTRSViatris	$19.22	+1.59%	+20.5%	+4.9%	−3.2%	—	$22.08B	Compare
ALNYAlnylam Pharmaceuticals	$161.08	+0.74%	−46.8%	+16.7%	148.6%	7.9	$21.57B	Compare
ZTSZOETIS	$89.20	+7.48%	−19.8%	−0.2%	28.0%	14.1	$36.86B	Compare
TEVATeva Pharmaceutical Industries Limited	$41.85	−0.14%	+15.2%	−0.8%	−13.9%	69.0	$48.81B	Compare
JAZZJazz Pharmaceuticals	$234.66	+2.14%	+2.7%	+10.4%	−38.9%	74.0	$15.23B	Compare

News about Roivant Sciences

All news →

Roivant and Priovant Announce Positive Results in CLARITY-1 and CLARITY-2 Phase 3 Trials for Brepocitinib in Non-Infectious Uveitis (NIU)GlobeNewswire Inc. · Oct 21, 2026▲ Positive Priovant Expands Brepocitinib Development Program with New Phase 2b/3 Trial in Lichen Planopilaris (LPP)GlobeNewswire Inc. · Apr 2, 2026▲ Positive New England Journal of Medicine Publishes Positive Phase 3 VALOR Trial Results of Brepocitinib in DermatomyositisGlobeNewswire Inc. · Mar 28, 2026▲ Positive

Quick answers

What does Roivant Sciences Ltd. Common Shares do?: Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business.
What is ROIV's market cap?: $27.61B, based on the Nov 4 close of $38.23.
Does Roivant Sciences Ltd. Common Shares pay a dividend?: No regular cash dividend has been paid in the last year.
How much of ROIV is sold short?: 40.3M shares, 8.0% of float, as of Oct 15, 2026.
What sector is ROIV in?: Healthcare, in the Pharmaceuticals industry.

About Roivant Sciences

Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.

HQ: London, 721 employeesListed Oct 1, 2021roivant.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology